Perlara is a full-stack drug discovery and development company focused on creating novel therapies for inherited metabolic diseases (IMDs), which are often neglected by larger pharmaceutical companies. Founded in 2014, Perlara utilizes a yeast-based model to explore and validate treatments for a variety of rare diseases, including congenital disorders of glycosylation, mitochondrial disorders, GPI-anchor defects, and tRNA-synthetase syndromes. The company's approach is characterized by its commitment to patient partnership, where each program is anchored by specific families or foundations, en…